11 Best Pharma Stocks to Invest in for the Long Term

8. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Number of Hedge Fund Holders: 28

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a California-based company specializing in complex generics and proprietary medicines, is strengthening its position in the pharmaceutical market with major manufacturing and product expansion initiatives.

A centerpiece of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s recent strategy is its plan to quadruple U.S. manufacturing capacity at its Rancho Cucamonga headquarters over the next few years. The project includes building a new state-of-the-art production plant with advanced automation and technology integration. By making all finished products domestically, the business aims to reduce reliance on global supply chains while creating new jobs in research, engineering, and manufacturing.

On the product side, the corporation recently secured FDA approval for its generic Iron Sucrose Injection, a bioequivalent to Venofer, with a Q3 2025 launch targeting the $513 million U.S. market for iron deficiency anemia. Its pipeline includes four additional ANDAs, a biosimilar insulin candidate, and an exclusive licensing deal with Nanjing Anji Biotechnology for three novel proprietary peptides. These assets, which include candidates for cancer, novel taxane therapies, and retinal disease, reflect the company’s push into innovative and high-value treatments, solidifying its position among the best pharmaceutical stocks to watch.

Commercial momentum is also being driven by BAQSIMI, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s glucagon nasal powder for severe hypoglycemia, which recorded a 51% sales increase in the most recent quarter. The product’s strong performance highlights the company’s ability to successfully commercialize therapies that address urgent and chronic patient needs.